Reference 2021-20

REF: 2021-20          

Subject: Treatment of severe asthma      

 

 

Request:

Q1. How many patients have been treated (for any disease) in the last three months with:

  • Benralizumab
  • Omalizumab
  • Reslizumab
  • Mepolizumab

 

Q2. How many patients have been treated in the last three months, for asthma ONLY, with:

  • Dupilumab
  • Upadacitinib

 

Q3. How many patients have been treated (with any medication) for severe asthma in the last three months?  Of these patients, how many were children?

 

Response:

Q1. How many patients have been treated (for any disease) in the last three months with:
Benralizumab

Omalizumab

Reslizumab

Mepolizumab

0

14

0

5

Q2. How many patients have been treated in the last three months, for asthma ONLY, with:
Dupilumab

Upadacitinib

None
Q3. How many patients have been treated (with any medication) for severe asthma in the last three months?  Of these patients, how many were children? unable to identify those with severe asthma because they may be treated in outpatients as outpatients isn’t clinically coded